Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Izotropic ( (TSE:IZO) ).
Izotropic Corporation has entered into a debt settlement agreement to address outstanding interest payable on a promissory note. The company will issue 240,000 units, each consisting of a common share and a share purchase warrant, to settle $60,000 in accrued interest. This settlement is subject to the approval of the Canadian Securities Exchange, and the securities will have a statutory hold period of four months and one day.
Spark’s Take on TSE:IZO Stock
According to Spark, TipRanks’ AI Analyst, TSE:IZO is a Underperform.
Izotropic’s overall stock score is low, primarily due to significant financial challenges, including consistent revenue shortfalls, negative income, and unsustainable cash flows. Despite some positive technical indicators and promising corporate events suggesting potential future growth, the company’s current financial instability and negative valuation metrics weigh heavily on its stock score.
To see Spark’s full report on TSE:IZO stock, click here.
More about Izotropic
Izotropic Corporation is a medical device company focused on commercializing innovative, emerging technologies and imaging-based products for the accurate screening, diagnosis, and treatment of breast cancers.
Average Trading Volume: 44,047
Technical Sentiment Signal: Hold
Current Market Cap: C$20.32M
Find detailed analytics on IZO stock on TipRanks’ Stock Analysis page.